Finance

Lists
LKFT:NASDAQ
Lakefront Biotherapeutics NV - ADR
$28.44
-0.23%
(-0.065) 1D
Sep 1, 12:30:15 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LKFT...
Open
$28.41
High
$28.67
Low
$28.34
Mkt. cap
1.87B
Avg. vol.
233.62K
Volume
66.27K
52-wk high
$30.90
52-wk low
$25.68
Beta
0.27
Shares outstanding
65.90M
No. of employees
196
Open
$28.41
High
$28.67
Low
$28.34
Mkt. cap
1.87B
Avg. vol.
233.62K
Volume
66.27K
52-wk high
$30.90
52-wk low
$25.68
Beta
0.27
Shares outstanding
65.90M
No. of employees
196
Profile
Lakefront Biotherapeutics is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis. Wikipedia
About Lakefront Biotherapeutics NV - ADR
CEOPaul Stoffels | Paul Stoffels
Employees196
Founded1999
Headquarters-
SectorBiotechnology
Websitelakefrontbio.com
Analyst ratings
Based on 2 analysts giving stock ratings to LKFT in the past 3 months
Hold
Buy
0
Hold
2
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for LKFT in the last 3 months.
Highest
Current $28.44
$26.00 (-8.56%)
Average
$26.00 (-8.56%)
Lowest
$26.00 (-8.56%)
Analyst
Recommendation
Action
Price target
Projected
Date
Judah Frommer
Morgan Stanley
Hold
Reiterated
$26.00
-8.6%
08/31/2026
Brian Abrahams
RBC Capital
Hold
Reiterated
$26.00
-8.6%
08/10/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
EPS / Est. (EUR)
€0.03 / -€11.50
+100.26%beat
Revenue / Est. (EUR)
12.11M / 6.13M
+97.55%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
71.16M
900.82M
6.48M
12.11M
Cost of goods sold
84.73M
107.97M
35.76M
34.67M
Cost of revenue
84.73M
107.97M
35.76M
34.67M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
34.55M
32.29M
35.50M
22.50M
Operating expense
28.10M
170.00K
34.42M
20.95M
Total operating expenses
112.83M
108.14M
70.18M
55.62M
Operating income
-41.67M
792.68M
-63.70M
-43.51M
Other non operating income
-51.21M
74.15M
959.00K
223.00K
EBT including unusual items
-221.49M
783.16M
13.96M
2.01M
EBT excluding unusual items
-43.59M
835.73M
-26.04M
-14.75M
Income tax expense
-17.50M
666.00K
70.00K
70.00K
Effective tax rate
7.90%
0.09%
0.50%
3.48%
Other operating expenses
-6.44M
-32.12M
-1.08M
-1.55M
Net income
-202.11M
782.15M
14.49M
2.11M
Net profit margin
-284.02%
86.83%
223.61%
17.42%
Earnings per share
-0.18
12.27
0.21
0.03
Interest and investment income
9.91M
14.94M
12.90M
12.11M
Interest expense
-
-1.03M
-
-127.00K
Net interest expenses
9.91M
13.90M
12.90M
11.98M
Depreciation and amortization charges
-
-
-
-
EBITDA
-33.23M
800.91M
-55.48M
-41.99M
Gain or loss from assets sale
23.83M
-1.06M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps